At AACR this year, we debuted new datasets on NK cell therapy screening and MOA assessment on the Cypre Tumor Organoid Platform. Post-FDA's announcement, organoids and AI-enabled platforms were a highlight at the conference for Cypre, among an abundance of therapeutic data and precision medicine initiatives.

‍